Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$27,000.00
Identifying and investigating novel regulators of alpha-synuclein release in Parkinson's disease
FY 2024-25
Summary
Parkinson disease (PD) is a progressive neurodegenerative disease with no current disease-modifying treatments. A pathological hallmark of PD is the presence of aggregates primarily composed of a protein called alpha-synuclein (aSyn) in the brain. In cell and animal models of PD, aSyn aggregation disrupts cellular processes and may lead to cell death, making it a potential therapeutic target. Similarly, increasing aSyn levels in humans by both genetic and certain environmental risk factors increase risk of developing PD. An emerging hypothesis is that these aggregates may be released from cells and induce aggregation on neighboring cells, worsening disease progression. Recent efforts in the field have focused on preventing this spread by stopping disease associated-aSyn from entering healthy cells. However, less is known about how and why a cell releases aSyn in the first place. Challenges to tackling this issue: 1) there have been little targeted studies confirming favorable pathways toward disease-release; 2) tracking aSyn from cell to cell has many technical difficulties. To address these issues, we have established a cell-based system to explore this phenomenon in unprecedented detail. We will systematically delete genes localized to the area in a neuron where cellular release occurs - the presynaptic terminal - and see its effect on aSyn release. Once we have identified potential genes that modulate aSyn release, we will confirm that suppressing target proteins do not affect cell health and will prioritize top targets to downstream validation in animal models of PD. Identifying potential targets for aSyn release allows for a further understanding of how PD may develop in the brain, ultimately holding important implication for downstream targeting.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
529940
Name
Aftab Aysha
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identifying and investigating novel regulators of alpha-synuclein release in Parkinson's disease
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alpha-Synuclein; Cell-To-Cell Transmission; Neurodegenerative Disease; Parkinson'S Disease; Protein Misfolding
Abstract
Parkinson disease (PD) is a progressive neurodegenerative disease with no current disease-modifying treatments. A pathological hallmark of PD is the presence of aggregates primarily composed of a protein called alpha-synuclein (aSyn) in the brain. In cell and animal models of PD, aSyn aggregation disrupts cellular processes and may lead to cell death, making it a potential therapeutic target. Similarly, increasing aSyn levels in humans by both genetic and certain environmental risk factors increase risk of developing PD. An emerging hypothesis is that these aggregates may be released from cells and induce aggregation on neighboring cells, worsening disease progression. Recent efforts in the field have focused on preventing this spread by stopping disease associated-aSyn from entering healthy cells. However, less is known about how and why a cell releases aSyn in the first place. Challenges to tackling this issue: 1) there have been little targeted studies confirming favorable pathways toward disease-release; 2) tracking aSyn from cell to cell has many technical difficulties. To address these issues, we have established a cell-based system to explore this phenomenon in unprecedented detail. We will systematically delete genes localized to the area in a neuron where cellular release occurs - the presynaptic terminal - and see its effect on aSyn release. Once we have identified potential genes that modulate aSyn release, we will confirm that suppressing target proteins do not affect cell health and will prioritize top targets to downstream validation in animal models of PD. Identifying potential targets for aSyn release allows for a further understanding of how PD may develop in the brain, ultimately holding important implication for downstream targeting.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Aftab, Aysha
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~